Torrent Pharmaceuticals Limited is a key player in the Indian pharma sector, specializing in chronic and sub-chronic therapies like Cardiovascular and Central Nervous System.

The company recorded substantial growth with revenues of Rs. 3,302 crores and an operating EBITDA margin of 32.8% for Q2 FY'26.

India business growth was driven by cardiac and gastro therapies, while Brazil registered 21% growth, underscoring its strong international markets presence.

The US segment witnessed a 26% growth, benefitting from new launches and increased purchase volume of existing contracts.

Significant field force expansion and strategic product launches in India and Brazil suggest a focused approach on market penetration and growth.